Anika TherapeuticsSTU:AKP 65 OCF Yield % is 3.06 as of Jul. 08, 2026, which is 15% below its 10-year median of 3.62. GuruFocus rates STU:AKP with a GF Score™ of 65/100 and a GF Value™ of €17.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Anika Therapeutics ranks worse than 52.43% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Anika Therapeutics OCF Yield % Related Terms
Anika Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AKP vs LFCR, DERM, ASRT: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (STU:AKP) has a OCF Yield % of 3.06 as of Jul. 08, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Anika Therapeutics and its competitors. This is 15% below median its historical median of 3.62. According to the industry distribution chart, Anika Therapeutics ranks #528 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is Anika Therapeutics' OCF Yield % too high?
Anika Therapeutics' current OCF Yield % of 3.06 is 15% below median its 10-year median of 3.62. The Drug Manufacturers industry median OCF Yield % is 3.53. Anika Therapeutics' value of 3.06 is 13.3% below this industry median. Based on the distribution chart, Anika Therapeutics ranks #528 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anika Therapeutics has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' OCF Yield % compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #528 out of 1007 companies for OCF Yield %. This places Anika Therapeutics in the lower half of its industry. The industry median OCF Yield % is 3.53. Anika Therapeutics' value of 3.06 is 13.3% below this benchmark. While the company's 10-year median is 3.62 vs. the industry median of 3.53, Anika Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anika Therapeutics's current OCF Yield % of 3.06 is 13.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current OCF Yield % is 3.06, which is 15% below median its own 10-year median of 3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.89, compared to a current price of €13.80 — trading 22.9% below its estimated fair value. The current OCF Yield % is 3.06, which is 15% below median its 10-year median of 3.62 and 13.3% below the Drug Manufacturers industry median of 3.53. Anika Therapeutics' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current OCF Yield % is 3.06 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (STU:AKP) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of €13.80 is trading 22.9% below its estimated GF Value™ of €17.89.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AKP:
OCF Yield %: 3.06 (15% below median its 10-year median of 3.62)
GF Value™: €17.89 vs. price of €13.80 (22.9% below fair value)
Industry Position: 13.3% below the Drug Manufacturers median (#528 of 1007)
No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
65GF Score
Get the complete analysis for STU:AKP
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AKP has been successfully added to your 
